preceding RFA to Atezo+Bev for HCC patients

JRCT ID: jRCT1041200075

Registered date:15/12/2020

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: hepatocellular carcinoma
• Date of first enrollment: 18/01/2021
• Target sample size: 66
• Study type: Interventional
• Intervention(s): Radiofreuquency ablation, Atezolizumab and bevacizumab combination therapy

Outcome(s)

• Primary Outcome: Progression-free survival
• Secondary Outcome: Overall survival, Immunological response, Objective response rate, Tumor control rate, Subsequent therapy, Adverse events

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
• Exclude criteria: refractory ascites or pleural effusion; unsuitable for RFA, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Related Information

• Primary Sponsor: Yamashita Tatsuya